Industry News

Prestige Brands Holdings, Inc. today announced that it will issue its fiscal 2017 second quarter earnings release on Thursday, November 3, 2016 before the opening of the market. The Company will host a conference call to discuss the results that same morning at 8:30 a.m. ET. To access the call, listeners calling from within North America may dial 844-233-9440 about 15 minutes prior to the start of the call."/>
Prestige Brands Holdings, Inc. to Release Fiscal 2017 Second Quarter Earnings on November 3rd
Alliqua BioMedical, Inc., a regenerative technologies company committed to restoring tissue and rebuilding lives, today announced preliminary third quarter of fiscal year 2016 revenue results and timing and details of the third quarter financial results conference call.. Third Quarter Preliminary Revenue Estimate:. While the Company has not finalized its full financial results for the nine month period ended September 30, 2016, it expects third..."/>
Alliqua BioMedical, Inc. Announces Preliminary Third Quarter of Fiscal Year 2016 Revenue; Earnings Conference Call Scheduled for November 4th
Cardiovascular Systems, Inc. will host a live webcast of its fiscal 2017 first-quarter conference call on Wednesday, October 26, 2016, at 3:45 p.m. CT. Scott Ward, Chairman, President and Chief Executive Officer, and Larry Betterley, Chief Financial Officer, will discuss the company’ s results for its fiscal first quarter ended September 30, 2016, and its financial outlook."/>
Cardiovascular Systems to Webcast Fiscal 2017 First-Quarter Earnings Conference Call Wednesday, October 26
Vascular Solutions, Inc. today announced that it will host a live webcast of its third quarter conference call on Monday, October 24, 2016 at 3:30pm CDT. Vascular Solutions’ Chief Executive Officer, Howard Root, Chief Financial Officer, James Hennen and VP of Corporate Development, Phil Nalbone, will discuss the company’ s third quarter results. The company will issue an earnings news release after market close on Monday, October 24, 2016.."/>
Cepheid, Xpert ® Bladder Cancer Monitor, now commercially available in Germany and cleared for commercial availability in all countries accepting the CE Mark. Bladder cancer is the 5 th most common cancer in Europe, affecting over 150,000 patients annually 1,2 and is among the most expensive cancers on a cost per treatment basis 3, in part..."/>
New Bladder Cancer Test Could Reduce Number Of Invasive Procedures Required For Recurrence Monitoring
Idera Pharmaceuticals, Inc. today announced that it intends to offer and sell up to $50,000,000 of shares of its common stock in an underwritten public offering. In connection with this offering, Idera expects to grant the underwriters a 30- day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. All of the shares in the offering are to be sold by Idera."/>
Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock
Trinity Biotech plc concerning possible violations of federal securities laws. To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at The investigation concerns Trinity’ s October 4, 2016 announcement that it will withdraw its 510 premarket notification submission for the Meritas..."/>
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Trinity Biotech plc and Advises Investors with Losses to Contact the Firm
Press Ganey Holdings, Inc. today announced the introduction of its proprietary Nursing Performance Solution, an analytics tool designed to provide nurse leaders and their teams with a comprehensive, single-source view of the factors that are most associated with driving nursing excellence— quality, patient..."/>
Press Ganey Launches New Nursing Performance Solution
Catalent, Inc., the New Jersey-based leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has acquired Pharmatek Laboratories, Inc., a San Diego-based specialist in drug development and clinical manufacturing. Scott Ehrlich, Simone Collins and Yulia Terentyeva of Sklar Kirsh LLP led the deal team representing Catalent. "We are proud to have assisted Catalent..."/>
Sklar Kirsh Advises Catalent on Acquisition of Pharmatek Laboratories
VolitionRx Limited, a life sciences company focused on developing diagnostic tests for cancer, today announced the closing of its previously announced underwritten public offering of 2.25 million shares of common stock at a public offering price of $5.00 per share. The net proceeds are expected to be approximately $10.6 million, after deducting underwriting discounts, commissions and estimated offering expenses payable by Volition."/>
VolitionRx Limited Announces Closing of Public Offering of Common Stock
Ritter Pharmaceuticals, Inc., a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that the Company's Chief Executive Officer, Michael Step, presented at the 4th Microbiome R&D Business Collaboration Forum& Panel on October 4, 2016 in San Diego, CA. Step presented an overview of RP-G28, Ritter's lead product candidate which has the potential to..."/>
Ritter Pharmaceuticals Presents at the 4th Microbiome R&D Business Collaboration Forum
Cigna Corporation will release its Third Quarter 2016 financial results on Thursday, November 3, 2016 and will host a conference call on the same day. Third Quarter 2016 financial results will be released no later than 6:30 a.m. Management will review these results on a conference call beginning at 8:30 a.m. ET that same morning."/>
Cigna Corporation’s Third Quarter 2016 Earnings Release Details
Collegium Pharmaceutical said on Wednesday that it has filed a Supplemental New Drug Application to the US Food& Drug Administration to enhance the label for Xtampza ER. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The sNDA includes comparative..."/>
Collegium submits sNDA to FDA for abuse-deterrent, extended-release opioid, Xtampza ER
Taro Pharmaceutical Industries reported on Tuesday the appointment of Mariano Balaguer as vice president, chief financial officer and chief accounting officer with immediate effect. Balaguer has almost 20 years of senior management experience in finance with global companies including Novartis Consumer Health and Nestle. Most recently, Balaguer worked for the Global Strategic Portfolio Division of Henry Schein where he was responsible for..."/>
Taro names Mariano Balaguer as new CFO
Acorda Therapeutics reported on Tuesday that Michael Rogers has stepped down as its chief financial officer. However, Rogers will serve as a consultant to the company through the end of the year to ensure a smooth transition of roles. David Lawrence, Acorda's chief of business operations, has been appointed as the new chief, business operations and principal accounting officer."/>
Acorda reports resignation of CFO Michael Rogers
Immune Design reported on Tuesday the appointment of Sergey Yurasov, MD, PhD as senior vice president of Clinical Development and chief medical officer. Most recently, Dr Yurasov served as senior vice president of Clinical Development at Clovis Oncology, overseeing all clinical activities for its rociletinib, rucaparib and lucitanib programs, including regulatory approval and launch support for rociletinib and rucaparib. Previously, Dr Yurasov was..."/>
Immune Design names Dr Sergey Yurasov as SVP & chief medical officer
Dipexium Pharmaceuticals stated on Tuesday that it has been awarded the Small and Medium Enterprise designation by the European Medicines Agency. The SME designation is intended to help promote innovation and the development of new medicinal products by smaller firms. Companies with SME status are eligible to receive financial incentives as well as administrative and regulatory support through national and regional level programs."/>
Dipexium passes EMA's SME designation
Kindred Biosciences reported on Tuesday the receipt of a technical section complete letter for effectiveness from the US Food and Drug Administration's Center for Veterinary Medicine for Zimeta, approving the technical section. The basis for this complete letter was a successful multicentre, randomized, blinded, placebo-controlled pivotal study that enrolled 138 horses to assess the effectiveness of Zimeta for fever in horses."/>
Kindred Biosciences reports regulatory progress in NDA for Zimeta for fever in horses
NewLink Genetics Corporation reported on Tuesday the receipt of a USD24.8m contract to support the advanced development of the investigational rVSV? G-ZEBOV GP vaccine candidate, V920. This contract was awarded by the Biomedical Advanced Research and Development Authority of the US Department of Health and Human Services to a subsidiary of NewLink Genetics."/>
NewLink Genetics wins USD25m BARDA agreement for investigational Ebola Zaire vaccine V920
AMN Healthcare Services, Inc., healthcare's leader and innovator in workforce solutions and staffing services, will host a conference call to discuss its third quarter 2016 financial results on Thursday, November 3, 2016 at 5:00 p.m. Eastern Time. The Company also expects to issue an earnings news release on Thursday, November 3, 2016 after the close of market at approximately 4:15 p.m. Eastern Time. A live webcast of the call can be accessed..."/>
AMN Healthcare to Host Third Quarter 2016 Earnings Conference Call on Thursday, November 3, 2016
Teva Pharmaceutical Industries Ltd. today announced that it has agreed to sell assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Limited for an agreed value of GBP 603 million, subject to final approval from the European Commission. The divestment of certain specified Actavis Generics assets and operations in the UK and Ireland was part of an undertaking that Teva made to the European Commission in the context of the review of the..."/>
Teva Announces Sale of UK and Ireland Actavis Assets and Operations
Cascadian Therapeutics said on Tuesday that its board of directors has approved a plan for a reverse split of its common stock at a ratio of not less than one for four and not greater than one for ten, to increase its share price. In conjunction with the proposal, the company will hold a special meeting on 18 November 2016 to obtain stockholder approval for the reverse split. This reverse split will reduce the total authorized shares of the company's..."/>
Cascadian Therapeutics proposes reverse stock split
Centene Corporation, has earned a top rating for its Medicaid plan in Illinois from The National Committee for Quality Assurance. For 2016-2017 IlliniCare Health has earned a 3.5 star NCQA rating– the highest score among Medicaid health plans in Illinois. "We are honored to provide the best quality service and care to our members," said Michael Marrah, Plan President and CEO."/>
IlliniCare Health Top Rated Medicaid Plan in Illinois

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology821 Articles
Consumer Discretionary711 Articles
Financials640 Articles
Health Care460 Articles
Industrials456 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at